Previous studies have confirmed the efficacy of p38 inhibitors by the downregulating of p38 MAPK, which is reported to have neuroprotective effects that can reduce the extent of cerebral ischemia, reduce the loss of neurons [37, 47, 48], and improve LV function [49]. The gene discussed is MAPK14; the disease is Cerebral ischemia.